255 related articles for article (PubMed ID: 11249709)
1. Gd-Tex Pharmacyclics Inc.
Radford IR
Curr Opin Investig Drugs; 2000 Dec; 1(4):524-8. PubMed ID: 11249709
[TBL] [Abstract][Full Text] [Related]
2. Motexafin gadolinium: gadolinium (III) texaphyrin, gadolinium texaphyrin, Gd-Tex, GdT2B2, PCI 0120.
Drugs R D; 2004; 5(1):52-7. PubMed ID: 14725495
[TBL] [Abstract][Full Text] [Related]
3. A phase I single-dose trial of gadolinium texaphyrin (Gd-Tex), a tumor selective radiation sensitizer detectable by magnetic resonance imaging.
Rosenthal DI; Nurenberg P; Becerra CR; Frenkel EP; Carbone DP; Lum BL; Miller R; Engel J; Young S; Miles D; Renschler MF
Clin Cancer Res; 1999 Apr; 5(4):739-45. PubMed ID: 10213207
[TBL] [Abstract][Full Text] [Related]
4. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
5. Tezacitabine Hoechst Marion Roussel.
Seley KL
Curr Opin Investig Drugs; 2000 Sep; 1(1):135-40. PubMed ID: 11249589
[TBL] [Abstract][Full Text] [Related]
6. Exisulind Cell Pathways.
Griffiths GJ
Curr Opin Investig Drugs; 2000 Nov; 1(3):386-91. PubMed ID: 11249724
[TBL] [Abstract][Full Text] [Related]
7. Thymitaq (Zarix).
Niculescu-Duvaz I
Curr Opin Investig Drugs; 2001 May; 2(5):693-705. PubMed ID: 11569949
[TBL] [Abstract][Full Text] [Related]
8. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
9. Technology evaluation: tgDCC-E1A, targeted genetics/MD Anderson.
Wagner JA
Curr Opin Mol Ther; 1999 Apr; 1(2):266-70. PubMed ID: 11715950
[TBL] [Abstract][Full Text] [Related]
10. ZD-9331 AstraZeneca.
Niculescu-Duvaz I
Curr Opin Investig Drugs; 2000 Sep; 1(1):141-9. PubMed ID: 11249590
[TBL] [Abstract][Full Text] [Related]
11. Lessons learned from independent central review.
Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
[TBL] [Abstract][Full Text] [Related]
12. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
[TBL] [Abstract][Full Text] [Related]
13. Bexarotene ligand pharmaceuticals.
Hurst RE
Curr Opin Investig Drugs; 2000 Dec; 1(4):514-23. PubMed ID: 11249708
[TBL] [Abstract][Full Text] [Related]
14. Re-evaluating gadolinium(III) texaphyrin as a radiosensitizing agent.
Bernhard EJ; Mitchell JB; Deen D; Cardell M; Rosenthal DI; Brown JM
Cancer Res; 2000 Jan; 60(1):86-91. PubMed ID: 10646858
[TBL] [Abstract][Full Text] [Related]
15. TP-10 (AVANT Immunotherapeutics).
Rioux P
Curr Opin Investig Drugs; 2001 Mar; 2(3):364-71. PubMed ID: 11575706
[TBL] [Abstract][Full Text] [Related]
16. The American Society for Therapeutic Radiology and Oncology (ASTRO) evidence-based review of the role of radiosurgery for brain metastases.
Mehta MP; Tsao MN; Whelan TJ; Morris DE; Hayman JA; Flickinger JC; Mills M; Rogers CL; Souhami L
Int J Radiat Oncol Biol Phys; 2005 Sep; 63(1):37-46. PubMed ID: 16111570
[TBL] [Abstract][Full Text] [Related]
17. Oblimersen: Augmerosen, BCL-2 antisense oligonucleotide - Genta, G 3139, GC 3139, oblimersen sodium.
Drugs R D; 2007; 8(5):321-34. PubMed ID: 17767397
[TBL] [Abstract][Full Text] [Related]
18. Endostatin (EntreMed).
Grosios K
IDrugs; 2000 Jul; 3(7):799-810. PubMed ID: 16080055
[TBL] [Abstract][Full Text] [Related]
19. Etanercept Immunex.
Yung RL
Curr Opin Investig Drugs; 2001 Feb; 2(2):216-21. PubMed ID: 11816834
[TBL] [Abstract][Full Text] [Related]
20. Optimizing cancer radiotherapy with 2-deoxy-d-glucose dose escalation studies in patients with glioblastoma multiforme.
Singh D; Banerji AK; Dwarakanath BS; Tripathi RP; Gupta JP; Mathew TL; Ravindranath T; Jain V
Strahlenther Onkol; 2005 Aug; 181(8):507-14. PubMed ID: 16044218
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
